2895-21-8

Basic information

• Product Name: N-ISOPROPYL-2-CHLOROACETAMIDE
• Synonyms: 2-chloro-N-propan-2-yl-ethanamide;2-chloro-N-isopropylacetamide(SALTDATA: FREE);2-Chloro-N-(prop-2-yl)acetamide, N-(Chloroacetyl)isopropylamine;Acetamide, 2-chloro-N-(1-methylethyl)-;2-CHLORO-N-ISOPROPYLACETAMIDE;AKOS USSH-4110464;BUTTPARK 80\07-100;N1-ISOPROPYL-2-CHLOROACETAMIDE
• CAS NO: 2895-21-8
• Molecular Formula: C₅H₁₀ClNO
• Molecular Weight: 135.59
• EINECS: 220-775-0
• Mol File: 2895-21-8.mol

Chemical Properties

• Melting Point: 58-60°C
• Boiling Point: 250.6°Cat760mmHg
• Flash Point: 105.4°C
• Appearance: /
• Density: 1.052g/cm³
• Vapor Pressure: 0.0215mmHg at 25°C
• Refractive Index: 1.435
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Acetone, Chloroform, Dichloromethane, DMSO, Ethyl Acetate, Methanol
• PKA: 14.08±0.46(Predicted)
• BRN: 1745034
• CAS DataBase Reference: N-ISOPROPYL-2-CHLOROACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ISOPROPYL-2-CHLOROACETAMIDE(2895-21-8)
• EPA Substance Registry System: N-ISOPROPYL-2-CHLOROACETAMIDE(2895-21-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 2895-21-8(Hazardous Substances Data)

Usage

Uses

Used in Pesticide Detection:
N-ISOPROPYL-2-CHLOROACETAMIDE is used as an intermediate in the synthesis of Prothoate (P838810), which is an organophosphorus pesticide. It is utilized as an analyte in the analytical study of a new method for detecting multi-residue organophosphorus pesticides, contributing to the development of more efficient and accurate detection techniques in the agricultural and environmental sectors.

InChI:InChI=1/C5H10ClNO/c1-4(2)7-5(8)3-6/h4H,3H2,1-2H3,(H,7,8)

Upstream product

• 71985-57-4 2-benzenesulfonyl-2-chloro-1-isopropyl-aziridine 
• 71985-56-3 2-chloro-2-(2-chloro-propane-2-sulfonyl)-1-isopropyl-aziridine 
• 75-31-0 isopropylamine 
• 79-04-9 chloroacetyl chloride 
• 7572-29-4 dichloroethyne 

Downstream Products

• 98379-83-0 2-(4-Chloro-phenoxy)-N-isopropyl-acetamide 
• 57186-77-3 N-Isopropyl-phenoxy-acetamid 
• 1192313-88-4 1,1-dimethylethyl 4-[(6-[4-fluoro-3-(trifluoromethyl)phenyl]-5-{2-[(1-methylethyl)amino]-2-oxoethyl}-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazin-2-yl)oxy]-1-piperidinecarboxylate 
• 1192313-24-8 3-[(6-(3-chlorophenyl)-5-{2-[(1-methylethyl)amino]-2-oxoethyl}-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazin-2-yl)oxy]propyl acetate 
• 1192313-25-9 3-{[6-(3-chlorophenyl)-4-({2-[(1-methylethyl)amino]-2-oxoethyl}oxy)pyrazolo[1,5-a]pyrazin-2-yl]oxy}propyl acetate 
• 1192313-10-2 2-[6-(3-chloro-2-fluorophenyl)-4-oxo-2-{[3-(1-piperidinyl)propyl]oxy}pyrazolo[1,5-a]pyrazin-5(4H)-yl]-N-(1-methylethyl)acetamide hydrochloride salt 
• 1192313-70-4 C₁₈H₁₅F₄IN₄O₂ 
• 1192313-69-1 2-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-2-iodo-4-oxopyrazolo[1,5-a]pyrazin-5(4H)-yl]-N-(1-methylethyl)acetamide 
• 3928-03-8 O,O-Dimethyl-S-isopropylcarbamoylmethyldithiophosphat 
• 2275-18-5 prothoate 
• 71985-71-2 N-Isopropyl α-phenylsulfonylacetamid 

Relevant articles and documents

Chirality sensing and size discrimination of anions by macrotricyclic cyclen-disodium complexes

Two macrotricyclic ligands composed of two face-to-face octadentate metal chelates were synthesized. These cage-shaped disodium complexes had special recognition ability for various counter anions. Specific chiral dicarboxylates bound to the complexes within the cavity and exhibited chirality induction properties. For instance, N-Boc-Asp dianion strongly induced circular dichroism (CD) signals, but N-Boc-Glu dianion, which is one carbon longer, did not. Chirality on Na+: The first example of chirality sensing on Na+ was achieved by a macrotricyclic host composed of two octadentate cyclen-Na+ complexes. Chiral N-Boc-Asp dianions coordinated to the Na+ at the cavity, resulting in the chirality induction of the cage molecule, but N-Boc-Glu dianion, which is one carbon longer, did not.

Palladium-Catalyzed β-C(sp3)-H Arylation of Aliphatic Ketones Enabled by a Transient Directing Group

The direct arylation of aliphatic ketones has been developed via Pd-catalyzed β-C(sp3)-H bond functionalization with 2-(aminooxy)-N,N-dimethylacetamide as a novel transient directing group (TDG), which showed remarkable directing ability to generate arylated products in moderate to good yields. Furthermore, the reaction can tolerate abundant substrate of ketones and aryl iodides. This study expands the scope of applications for TDGs.

4-Arylthieno[2,3-b]pyridine-2-carboxamides Are a New Class of Antiplasmodial Agents

Malaria causes hundreds of thousands of deaths every year, making it one of the most dangerous infectious diseases worldwide. Because the pathogens have developed resistance against most of the established anti-malarial drugs, new antiplasmodial agents are urgently needed. In analogy to similar antiplasmodial ketones, 4-arylthieno[2,3-b]pyridine-2-carboxamides were synthesized by Thorpe-Ziegler reactions. In contrast to the related ketones, these carboxamides are only weak inhibitors of the plasmodial enzyme PfGSK-3 but the compounds nevertheless show strong antiparasitic activity. The most potent representatives inhibit the pathogens with IC50values in the two-digit nanomolar range and exhibit high selectivity indices (>100).

PROCESS FOR PREPARATION OF ERDAFITINIB, ITS PURIFICATION AND AMORPHOUS SOLID DISPERSION

An aspect of the present application provides a process for the preparation of Erdafitinib and its pharmaceutically acceptable salts. Another aspect of the present application relates to amorphous solid dispersions of Erdafitinib, process for the preparation thereof and pharmaceutical composition comprising amorphous solid dispersions of Erdafitinib. Another aspect of the present application provides process for purification of Erdafitinib.

GLUCOSE UPTAKE INHIBITORS

this invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

Novel vanillin derivatives containing a 1,3,4-thiadiazole moiety as potential antibacterial agents

In this study, thirty-four novel vanillin derivatives containing a 1,3,4-thiadiazole structure were obtained and their antibacterial activities were evaluated. The results indicate that most of the title compounds displayed inhibitory effects on Xanthomonas oryzae pv. oryzae (Xoo) and Xanthomonas oryzae pv. oryzicola (Xoc). Among them, compound 29 exhibited excellent antibacterial activities against Xoo and Xoc in vitro, with the EC50 values of 3.14 and 8.83 μg/mL, respectively, much superior to thiodiazole copper (87.03 and 108.99 μg/mL) and bismerthiazol (67.64 and 79.26 μg/mL). Under greenhouse condition, the protective efficiency of compound 29 against rice bacterial leaf blight was 49.34%, and curative efficiency was 40.96%. In addition, compound 29 can reduce the exopolysaccharides production of Xoo, increase the permeability of cell membrane and damage cell membrane.

Design, Synthesis, and Bioactivity of α-Ketoamide Derivatives Bearing a Vanillin Skeleton for Crop Diseases

A series of novel α-ketoamide derivatives bearing a vanillin skeleton were designed and synthesized. Bioactivity tests on virus and bacteria were performed. The results indicated that some compounds exhibited excellent antitobacco mosaic virus (TMV) activities, such as compound 34 exhibited an inactivation activity of 90.1percent and curative activity of 51.8percent and compound 28 exhibited a curative activity of 54.8percent at 500 μg mL-1, which is equivalent to that of the commercial ningnanmycin (inactivation of 91.9percent and curative of 51.9percent). Moreover, the in vitro antibacterial activity test illustrated that compounds 2, 22, and 33 showed much higher activities than commercial thiodiazole copper, which could be used as lead compounds or potential candidates. The findings of transmission electron microscopy and molecular docking indicated that the synthesized compounds exhibited strong and significant binding affinity to the TMV coat protein and could obstruct the self-assembly and increment of TMV particles. This study revealed that α-ketoamide derivatives bearing a vanillin skeleton could be used as a novel potential pesticide for controlling the plant diseases.

Continuous-Flow Electrosynthesis of Benzofused S-Heterocycles by Dehydrogenative C?S Cross-Coupling

Reported herein is the synthesis of benzofused six-membered S-heterocycles by intramolecular dehydrogenative C?S coupling using a modular flow electrolysis cell. The continuous-flow electrosynthesis not only ensures efficient product formation, but also obviates the need for transition-metal catalysts, oxidizing reagents, and supporting electrolytes. Reaction scale-up is conveniently achieved through extended electrolysis without changing the reaction conditions and equipment.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors

PI3K/Akt/mTOR signaling pathway plays an important role in cancer cell growth and survival. In this study, a new class of molecules with skeleton of 4-phenyl-2H-benzo[b] [1,4]oxazin-3(4H)-one were designed and synthesized targeting this pathway. Bioassays showed that, among all the molecules, 8d-1 was a pan-class I PI3K/mTOR inhibitor with an IC50 of 0.63 nM against PI3Kα. In a wide panel of protein kinases assays, no off-target interactions of 8d-1 were identified. 8d-1 was orally available, and displayed favorable pharmacokinetic parameters in mice (oral bioavailability of 24.1%). In addition, 8d-1 demonstrated significant efficiency in Hela/A549 tumor xenograft models (TGI of 87.7% at dose of 50 mg/kg in Hela model) without causing significant weight loss and toxicity during 30 days treatment. Based on the bioassays, compound 8d-1 could be used as an anti-cancer drug candidate.